Last updated on April 2018

Pembrolizumab and GM-CSF in Biliary Cancer


Brief description of study

This is an open label phase II trial to examine efficacy and safety of a novel combination of pembrolizumab plus induction GM-CSF in patients with advanced biliary cancers treated at UCSF.

This phase II study will examine the efficacy and safety of the novel combination of pembrolizumab plus induction GM-CSF in advanced biliary cancer patients with the hypotheses that the combination may increase proportion of patients with overall response compared to contemporary historical controls, with acceptable safety.

Clinical Study Identifier: NCT02703714

Contact Investigators or Research Sites near you

Start Over

Lesley McCarthy, RN

UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA United States
  Connect »